Key points are not available for this paper at this time.
Abstract Lipoprotein‐associated phospholipase A 2 (Lp‐PLA 2 ) is associated with increased risk of cardiovascular diseases (CVD) and type 2 diabetes mellitus. Lp‐PLA 2 activity is positively associated with male sex, Caucasian race, the presence of metabolic syndrome (MetS) and low‐density lipoprotein (LDL)‐cholesterol, but it is negatively associated with high‐density lipoprotein (HDL)‐cholesterol. Associations with other cardiometabolic risk factors, inflammation markers, and lifestyle factors are few or inconsistent. We investigated potential determinants of Lp‐PLA 2 activity among both nonmodifiable and modifiable CVD risk factors in a middle‐aged Greek cohort without overt CVD. Two hundred eighty four subjects (159 men, 53 ± 9 years and 125 women 52 ± 9 years) participated in a cross‐sectional study carried out during 2011–2012 in Athens, Attica. Cardiometabolic risk factors, inflammation markers, lifestyle factors, and Lp‐PLA 2 activity were evaluated with established methods. The American Heart Association/National Heart, Lung, and Blood Institute (AHA/NHLBI) criteria were used to define MetS. Lp‐PLA 2 activity was not associated with MetS, but was associated with MetS components, markers of liver function, and macronutrient intake. Increased total energy intake was associated with increased Lp‐PLA 2 activity (odds ratio, 95% confidence interval: 1.07, 1.01–1.14 and 1.10, 1.03–1.16 for the 4th and 3rd quartiles, respectively, compared to the 1st quartile) after adjustments for sex, pack‐years of smoking, LDL‐cholesterol, and statin treatment. Adiponectin tended to be inversely associated with Lp‐PLA 2 activity (0.91, 0.82–1.00, and 4th versus 1st quartile). Our results suggested that total energy intake and adiponectin levels are potential determinants of Lp‐PLA 2 activity.
Ntzouvani et al. (Fri,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: